Facebook Instagram Linkedin Youtube
Home Search

redwood pharma - search results

If you're not happy with the results, please do another search
Less money upfront for preclinical companies

Lower up-front payments for startups

Anders Kronborg

SynAct Pharma’s Chairman: ”We are confident we have the right strategy”

Investing in life science: From Seed to Success 2024

Adjutec ready to start phase I

AdjuTec Pharma to start phase I trial with APC148

Spago Nanomedical strengthened management to reflect project progress

Curasight proof of concept

Curasight targets clinical proof-of-concept for uTREAT

Peter Hovstadius

Lipum recruits new CMO: “I have been following their research for...

BioStock: Alzinova’s CEO - “we are a top actor in the Alzheimer’s field”

Alzinova’s CEO: “We are a top actor in the Alzheimer’s field”

Dansk pole position

Danish pole position among best Nordic life science stocks in H1

Åsa Magnusson

Lipum strengthens the board with commercial expertise

Arcede liquidated

Arcede Pharma heading towards liquidation

SynAct

SynAct Pharma moves forward with filing process

Alligator Fas II-data

“Unprecedented” phase II data for Alligator in pancreatic cancer

Spermosens: helping couples succeed in babymaking 

Annexin

Annexin comments on acquisition and focus on ANXV in ophthalmology

Aqilion and Merck end collaboration

Aqilion and Merck sever ties

Curasight presents funding package

Curasight CEO comments on capital raise and milestone

BioStock Global Forum 2024

Ablivas CEO: "We remain on track for the interim analysis early in Q3"

Ablivas CEO: “We remain on track for the interim analysis early...

AdjuTech gets green light

AdjuTec advances toward phase I with regulatory green light

Full focus on financing and new CEO for Arcede

Full focus on financing and new CEO for Arcede

Lipum

Flerie Invest continues to support Lipum

Arcede results

New results confirmation for Arcede Pharma

Spago Q1 2024 progress tumorad

Spago’s CEO: Advancing the Tumorad programme comes first

SynAct

SynAct Pharma’s CEO provides an update

AlligatorOrionMilestonePayment (1)

Orion option exercise triggers milestone payment for Alligator

Oncoinvent

Oncoinvent strengthens board and cash position

Synact focuses on pushing forward rheumatoid arthritis project

Synact focuses on pushing forward rheumatoid arthritis project

Spago_radiopharma_commercial_opportunity

Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Per Norlén, CEO WntResearch

WntResearch’s new CEO comments on his first month in the position

SynAct

Synact’s new CEO: “I’m hitting the ground running”

Alligators vd om den aktuella utvecklingen och företrädesemissionen

Alligator’s CEO on current development and the rights issue

Swiss Nordic Bio

Chordate’s CEO presented at Swiss Nordic Bio

Thomas Feldthus, CEO Saniona

Saniona’s CEO: “Our development pipeline is stronger than ever”

Evaxion partners with MSD for vaccine development

Evaxion partners with MSD for vaccine development

Prolight Diagnostics goals

Prolight Diagnostics CEO: “We deliver on all goals”

Adjutec prepares for clinical trial

Adjutec applies for phase I start

Positive signals from the U.S.

U.S. biotechs raise more capital

Full speed ahead for Elicera in 2024

Full speed ahead for Elicera in 2024

Curasight accelerates with rights issue

Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

SynAct

Deep dive into SynAct Pharma’s new strategy

Curaight gets milestone payment

Curasight gets first milestone payment from Curium

Oncoinvent

Oncoinvent’s CEO: “Radiopharmaceuticals has emerged as the hottest space in oncology”

SynAct Board

Major shareholders in SynAct Pharma request board change

Saniona’s CEO: “financing will bring SAN711 towards proof of concept”

Saniona’s CEO: “financing will bring SAN711 towards proof of concept”

ADC deals

Targinta’s CEO: “Strong interest in ADCs in 2023” 

Neola Medical attended JPMorgan Health Conference

Neola’s rapid development recognised at JPMorgan

A new proposal could provide support for drug developers lite Adjutec Pharma

New proposal potential game changer for Adjutec Pharma

BioStock lists the strongest and the weakest stocks in life science of 2023.

2023’s strongest and weakest life science stocks

Alzinova's CMO wants to bring forward a vaccine against Alzheimer's

Alzinova’s CMO wants to bring forward a vaccine against Alzheimer’s

Arcede Pharma prepareds for phase I

Arcede aims for clinic with TO1

New acting CEO in Arcede Pharma

Arcede Pharma appoints acting CEO

Evaxion unveils refined business strategy

Evaxion unveils refined business strategy

BioInvents vd: “Vi gjorde enastående framsteg i år”

BioInvent’s CEO: “This year we made unprecedented progress”

Promore carries out reverse takeover

Promore carries out reverse acquisition and changes its operations

Elicera_Legend_Novartis agreement

CAR T deal puts spotlight on Elicera’s technology

Curasight accelerates the development of uTREAT

Curasight CEO: “Working on accelerated plan for uTREAT”

BIO-Europe

Lipum’s SOL-116 sparked interest at BIO-Europe 

Toleranzia stegar på

Arcede proceeds to stability study in collaboration with Iconovo

Arcede Pharmas RCD405 well tolerated

Arcede Pharma approaches clinical trial after toxicological results

123...6Page 1 of 6
© BioStock 2024